The phase III study DESTINITY-Breas 06 [32] evaluates T-Dxd compared to the researcher’s choice of chemotherapy in patients with metastatic HER2-low breast cancer who have positive hormone receptors and whose disease has progressed on endocrine therapy. Here, ERBB2 is linked to breast cancer.